Reducing immune reactions to cancer treatment drugs
Official title: Mitigating ADA Through Site-specific Conjugation Technology
Funded at State University of Ny,binghamton · NIH-10995276 · Data updated 2026-11-12
This study is testing a new way to make cancer treatments called antibody drug conjugates (ADCs) safer and more effective by helping them avoid triggering unwanted immune responses, which could make the treatment work better for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of Ny,binghamton NIH-funded |
| Lab location | 1 site (Binghamton, United States) |
| Project start | November 21, 2022 |
| Project end | May 16, 2025 |
| Funding year | 2025 |
| Award (this year) | $25,789 |
| NIH project number | 5F31GM148053-03 |
| Project ID | NIH-10995276 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing treatment with antibody drug conjugates for cancer.
✕Less likely to help
Patients who are not receiving antibody drug conjugates or those with conditions unrelated to cancer may not benefit from this research.
What this research studies
This research investigates a new technology designed to improve antibody drug conjugates (ADCs) used in cancer therapy by reducing the immune response that can occur when patients receive these treatments. The approach focuses on modifying how the drug is attached to the antibody to minimize the development of anti-drug antibodies (ADAs), which can neutralize the drug's effectiveness and cause allergic reactions. By using advanced techniques like NMR and fluorescence, the researchers aim to demonstrate that their method can effectively hide the drug from the immune system, potentially leading to safer and more effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies with fewer side effects for patients.
How similar studies have gone: Other research has shown promise in reducing immune responses to similar therapies, indicating that this approach may be viable.
Where this research is happening
-
State University of Ny,binghamton
Binghamton, United States Active
Researchers
- Principal investigator: Benjamin, Samantha Rene — State University of Ny,binghamton
- Study coordinator: Benjamin, Samantha Rene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.